Item 8.01 Other Events.

On June 1, 2021, Alkermes plc issued a press release announcing that the U.S. Food and Drug Administration has approved LYBALVITM (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference in this Item 8.01.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits




Exhibit
No.          Description

99.1           Press release issued by Alkermes plc dated June 1, 2021.
104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses